Prior outlook $3.07B-$3.12B. Consensus $3.10B. Sees 2025 adjusted EBITDA $455M-$475M vs. prior $425M-$455M.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on EXAS:
- Exact Sciences reports Q2 EPS (1c), consensus (15c)
- Exact Sciences’ Growth Potential Bolstered by Cologuard Plus and Strategic Medicare Advantage Agreement
- EXAS Upcoming Earnings Report: What to Expect?
- Exact Sciences expands colorectal cancer screening partnership with Humana
- Buy Rating for Exact Sciences Driven by Promising CRC Screening Test and Favorable Market Outlook